Related Experiment Video
Updated: Jul 6, 2026
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Identification of Novel Biomarkers of Bacterial Lipopolysaccharides in Diabetic Nephropathy via Transcriptomics and
Yaxian Ning1,2, Jianqin Wang1,2, Xiaochun Zhou1,2
1Department of Nephrology, Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China.
Background:
Dysbiosis of Intestinal Flora Lipopolysaccharides (LPS) is implicated in Diabetic Nephropathy (DN), yet the underlying mechanisms remain unclear. This study aims to elucidate the causal relationship between bacterial LPS and DN, with the goal of informing targeted therapeutic strategies.
Methods:
DN datasets GSE30528 and GSE96804 were analyzed. Bacterial LPS-related genes (LPS-RGs) were retrieved from the Gene Set Enrichment Analysis (GSEA) database. Differential expression analysis identified differentially expressed genes (DEGs), which were cross-referenced with LPS-RGs to derive DE-LPS-RGs. Mendelian randomization (MR) was applied to explore correlations between exposure factors and outcomes using GWAS data. miRNA-mRNA and TFmRNA regulatory networks were constructed using data from the TarBase and ENCODE databases, and potential therapeutic agents were identified through the DGIdb database.
Results:
Seven DE-LPS-RGs were identified, with CD14 and LY86 selected as biomarkers. GSEA and GeneMANIA analyses indicated that these genes participate in signal transduction and chargelike receptor signaling pathways. The regulatory networks demonstrated that LY86 interacts with miRNA hsa-mir-26a-5p, while TF ELK1 regulates both CD14 and LY86. Additionally, CD14 was associated with three potential drugs: VB-201, IC14, and Lovastatin.
Conclusion:
CD14 and LY86 represent promising biomarkers for DN, offering new perspectives for its prediction, diagnosis, and therapeutic intervention.
